Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
17 April 2000Website:
http://www.exelixis.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
regular market | 1 min agoDividend
Analysts recommendations
Institutional Ownership
EXEL Latest News
Explore how Exelixis' (EXEL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
EXEL tops on earnings and sales in the third quarter as lead drug Cabometyx maintains momentum. The company also raises its revenue guidance for 2024.
Exelixis, Inc. (NASDAQ:EXEL ) Q3 2024 Earnings Conference Call October 29, 2024 5:00 PM ET Company Participants Varant Shirvanian - Director, IR Michael Morrissey - President & CEO Christopher Senner - EVP & CFO Amy Peterson - EVP, Product Development, Medical Affairs & Chief Medical Officer Dana Aftab - Chief Scientific Officer P.J. Haley - EVP, Commercial Conference Call Participants Asthika Goonewardene - Truist Chi Fong - Bank of America Silvan Tuerkcan - Citizens JMP Michael Schmidt - Guggenheim Securities Gregory Renza - RBC Capital Markets Yaron Werber - TD Cowen Jay Olson - Oppenheimer Andy Hsieh - William Blair Ashwani Verma - UBS Peter Lawson - Barclays Lukas Shumway - BMO Capital Markets Sudan Loganathan - Stephens Chris Shibutani - Goldman Sachs Joseph Catanzaro - Piper Sandler Operator Good day, ladies and gentlemen, and welcome to Exelixis Third Quarter 2024 Financial Results Conference Call.
The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Exelixis (EXEL) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.10 per share a year ago.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Does Exelixis (EXEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The small cap biotech sector is trading close to the same levels that it was five years ago. Straight equity holdings have threaded water in this space over the past half decade. However, given the lucrative option premiums available against many names in this area, a covered call strategy has worked quite successfully for my portfolio on a consistent basis.
Exelixis' stock has surged 51% since July 2023, significantly outperforming broader markets and breaking out of a five-year stagnation. Cabometyx, EXEL's primary revenue driver, continues to excel in renal cell carcinoma, generating strong sales and bolstering financial stability. The company settled patent disputes, delaying generic entry for Cabometyx until 2031, providing a critical extension of its revenue stream.
What type of business is Exelixis?
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
What sector is Exelixis in?
Exelixis is in the Healthcare sector
What industry is Exelixis in?
Exelixis is in the Biotechnology industry
What country is Exelixis from?
Exelixis is headquartered in United States
When did Exelixis go public?
Exelixis initial public offering (IPO) was on 17 April 2000
What is Exelixis website?
https://www.exelixis.com
Is Exelixis in the S&P 500?
No, Exelixis is not included in the S&P 500 index
Is Exelixis in the NASDAQ 100?
No, Exelixis is not included in the NASDAQ 100 index
Is Exelixis in the Dow Jones?
No, Exelixis is not included in the Dow Jones index
When was Exelixis the previous earnings report?
No data
When does Exelixis earnings report?
Next earnings report date is not announced yet